Navigation Links
Bionovo Announces 2009 Highlights and Year-End Financial Results
Date:3/15/2010

ntial pharmacological uses. In addition, our studies have indicated that these compounds do not promote breast or endometrial cancer in animal models, unlike estrogen therapies. This suggests that these ER beta-selective compounds could lead to safer, more appealing therapies for menopausal disorders.
  • Publication of final study results from our Phase 1B trial of Bezielle for metastatic breast cancer. Bezielle showed an excellent safety and tolerability profile. It also showed promising early efficacy in a difficult-to-treat population, including stable disease and tumor regression.
  • International presentation of final study results from our Phase 2 trial of Menerba for menopausal vasomotor symptom treatment. These results included:
    • After 12 weeks of treatment, there was a statistically significant decrease in frequency of all hot flashes in the higher dose of Menerba (p=0.04).
    • There was a clear dose response trend in multiple efficacy analyses.
    • Menerba reduced the number of times women were awakened from sleep due to hot flashes (night sweats). The median percent reduction in night sweats in the higher dose of Menerba was 67%, statistically superior to placebo (p=0.05).
    • Compliance and study retention was excellent: 98% of participants completed the trial, with 91% of participants taking at least 75% of the assigned study medication.
    • The only statistically significant adverse event was "transient loose stools" (12% on Menerba vs. 3% on placebo).
    • During the trial, there was no difference in the number of uterine bleeding episodes between the treatment g
      '/>"/>

    SOURCE Bionovo, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related medicine technology :

    1. Bionovo, Inc. to Announce Fourth Quarter and Fiscal Year 2009 Financial Results on Monday, March 15, 2010
    2. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
    3. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
    4. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2009 Financial Results on Thursday, November 5, 2009
    5. Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
    6. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
    7. Bionovos Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
    8. Bionovo Announces First Quarter 2009 Highlights and Financial Results
    9. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
    10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
    11. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
  • Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... 2014 ... has announced the addition of the ... to their offering.      (Logo: ... of chromosomes using molecular biology to understand ... chromosomes. It plays a crucial role in ...
    (Date:9/18/2014)... , Sept. 18, 2014  Low T ... committee meeting in Hyattsville, Maryland ... to assess the proper patient population for testosterone ... cardiovascular risk associated with TRT. Examining recent claims from ... found that "available epidemiological studies do not provide ...
    (Date:9/18/2014)... CITY, Kan. , Sept. 18, 2014 /PRNewswire/ ... a pet therapeutics company focused on licensing, developing ... today announced the full exercise of the underwriters, ... stock in connection with the company,s previously announced ...  All of the shares are being offered by ...
    Breaking Medicine Technology:Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
    (Date:9/18/2014)... 19, 2014 Today, Zane Benefits, the ... why to switch employees to individual health insurance. ... be more familiar with traditional, group health insurance, there ... employees happier. , The new article provides the ... health insurance rather than group health insurance, and why ...
    (Date:9/18/2014)... (PRWEB) September 19, 2014 Reduce bags ... ingredients made just for these issues in a serum. ... Haloxyl and Eyeliss," says Kathy Heshelow, founder of Sublime ... circulation and boosting collagen, to improve the eye area." ... serum for wrinkles, dark circles and bags at ...
    (Date:9/18/2014)... 19, 2014 When Mary Ann Thompson and Mathieu ... who live in Bali, Indonesia with their son, Isaac, said there ... two met at Mercy College in 2001 when Thompson was an ... was a graduate student at the time, was French and so ... and migrated to the United States when she was 7 years ...
    (Date:9/18/2014)... 18, 2014 Defendants in more ... currently pending in Pennsylvania’s Philadelphia Court of Common ... on behalf of out-of-state plaintiffs dismissed, Bernstein Liebhard ... 11th, the defendants maintain that circumstances surrounding the ... lawsuits have no connection to Pennsylvania. The filings ...
    (Date:9/18/2014)... Active Aging Week is a week-long observance ... members of society and promotes the benefits of leading ... a boutique retirement community located at 1200 Overlook Drive, ... of Cyber-Seniors - a humorous and heartwarming documentary. , ... this great film,” says Thomas Cloutier, Executive Director for ...
    Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Why Employees Are Happier with Individual Health Insurance 2Health News:The Secret to Improving Under-Eye Skin: 30% Off Sale and Report on Ingredients Ends Tonight on the Face Whisperer® Advanced Eye Gel 2Health News:For The First Time in Over a Decade Mercy College Alumni Marry at College 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3Health News:In Support of Active Aging Week, a Lake Oswego Retirement Community Will Get a Sneak Peek at an Inter-Generational Documentary – Cyber-Seniors 2
    ... Rehab MarketDETROIT, March 10 David Glancy, a complex ... has joined Alliance Seating & Mobility (ASM), ... companies. Glancy is an Assistive Technology Professional ... and provides power mobility solutions for pediatrics and adults ...
    ... WASHINGTON, March 10 To guide healthcare systems in ... the National Quality Forum (NQF) is releasing its 2009 ... pace of adoption of Safe Practices nationwide, a year-long ... Practices implementation strategies and commentary from experts in the ...
    ... soar past $2.5 trillion and more than 47 million people ... medical options to ensure health care reform is successful, argues ... Americans die each year because of their lack of insurance, ... that save very few lives or yield only a few ...
    ... of fondness and relief. Fondness for the good memories, and relief ... gossip, SATs, fights with parents is behind us. ... that even stressful times from the teenage years exact a physical ... , Andrew J. Fuligni, a professor of psychiatry at the ...
    ... ROCHESTER, Minn., March 10 Here are highlights from ... . You may cite this publication as often as ... attribution is required. Reprinting is allowed ... your editorial policies permit: Visit www.bookstore.mayoclinic.com or ...
    ... CPC of America, Inc. (OTC Bulletin Board: ... therapeutic devices that enhance the quality of patient ... is actively pursuing the development of proprietary polyethylene ... global commercialization strategy for MedClose(TM). MedClose(TM) is ...
    Cached Medicine News:Health News:Veteran Rehab Specialist, David Glancy, Joins Fast-Growing Alliance Seating & Mobility in Michigan 2Health News:'Patient Safety Can't Wait' - NQF Calls for Faster Spread of Safe Practices 2Health News:'Patient Safety Can't Wait' - NQF Calls for Faster Spread of Safe Practices 3Health News:'Patient Safety Can't Wait' - NQF Calls for Faster Spread of Safe Practices 4Health News:Limited resources, unlimited needs: Americans should ration health care, says MSU ethicist 2Health News:Limited resources, unlimited needs: Americans should ration health care, says MSU ethicist 3Health News:Teenage stress has implications for adult health 2Health News:March 2009 Mayo Clinic Women's HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women 2Health News:March 2009 Mayo Clinic Women's HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women 3Health News:March 2009 Mayo Clinic Women's HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women 4Health News:March 2009 Mayo Clinic Women's HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women 5Health News:March 2009 Mayo Clinic Women's HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women 6Health News:CPC Pursues Development of Proprietary Synthetic Sealants as part of MedClose(TM) Global Commercialization 2Health News:CPC Pursues Development of Proprietary Synthetic Sealants as part of MedClose(TM) Global Commercialization 3
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    Medicine Products: